Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch, Sjoerd A.M.E.G. Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, Esther Bulle, Frank E.H.P. van Baarle, Marcel C.G. van de Poll, E. Marleen Kemper, Iwan C.C. van der Horst, Marcus J. Schultz, Janneke Horn, Frederique Paulus, Lieuwe D. J. Bos, W. Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C. Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels C. Riedemann, Diederik van de Beek